Top

Annals of Hematology

Published in:

01-05-2021 | Acute Myeloid Leukemia | Letter to the Editor

Venetoclax-induced panniculitis in an acute myeloid leukemia patient

Authors: Po-Wei Liao, Ren Ching Wang, Tsung-Chih Chen, Chieh-Lin Jerry Teng

Published in: Annals of Hematology | Issue 5/2021

Excerpt

Dear Editor, …

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137–2145. https://doi.org/10.1182/blood.2020004856CrossRefPubMedPubMedCentral

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Dohner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hajek R, Porkka K, Illes A, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617–629. https://doi.org/10.1056/NEJMoa2012971CrossRefPubMed

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF (2018) Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res 24(18):4371–4379. https://doi.org/10.1158/1078-0432.CCR-17-3761CrossRefPubMed

DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216–228. https://doi.org/10.1016/S1470-2045(18)30010-XCrossRefPubMed

Michonneau D, Petrella T, Ortonne N, Ingen-Housz-Oro S, Franck N, Barete S, Battistella M, Beylot-Barry M, Vergier B, Maynadie M, Bodemer C, Hermine O, Bagot M, Brousse N, Fraitag S (2017) Subcutaneous panniculitis-like T-cell lymphoma: immunosuppressive drugs induce better response than polychemotherapy. Acta Derm Venereol 97(3):358–364. https://doi.org/10.2340/00015555-2543CrossRefPubMed

Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, Lasater EA, Shi Y, Dave N, Riehm JJ, Robinson VA, Do AD, Li Y, Orr CJ, Sampath D, Raval A, Merchant M, Bhathena A, Salem AH, Hamel KM, Leverson JD, Donawho C, Pappano WN, Uziel T (2020) Venetoclax increases intra-tumoral effector T cells and anti-tumor efficacy in combination with immune checkpoint blockade. Cancer Discov CD-19-0759. https://doi.org/10.1158/2159-8290.CD-19-0759

Fathi AT, DiNardo CD, Kline I, Kenvin L, Gupta I, Attar EC, Stein EM, de Botton S, Investigators ACS (2018) Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant Isocitrate dehydrogenase 2: analysis of a phase 1/2 study. JAMA Oncol 4(8):1106–1110. https://doi.org/10.1001/jamaoncol.2017.4695CrossRefPubMed

Title: Venetoclax-induced panniculitis in an acute myeloid leukemia patient
Authors: Po-Wei Liao
Ren Ching Wang
Tsung-Chih Chen
Chieh-Lin Jerry Teng
Publication date: 01-05-2021
Publisher: Springer Berlin Heidelberg
Keywords: Acute Myeloid Leukemia
Panniculitis
Panniculitis
Published in: Annals of Hematology / Issue 5/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04372-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2021

Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort

Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity?

Whole-body low-dose computed tomography (WBLDCT) in staging and re-staging of multiple myeloma

Daratumumab for refractory warm autoimmune hemolytic anemia

Clonal derivation of sequential seminoma and acute megakaryoblastic leukaemia

Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials